Phibro Animal Health/$PAHC

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Phibro Animal Health

Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.

Ticker

$PAHC
Primary listing

Industry

Pharmaceuticals

Employees

1,940

ISIN

US71742Q1067

PAHC Metrics

BasicAdvanced
$1B
32.19
$0.78
0.62
$0.48
1.91%

What the Analysts think about PAHC

Analyst ratings (Buy, Hold, Sell) for Phibro Animal Health stock.

Bulls say / Bears say

Phibro Animal Health reported a significant 85% increase in Adjusted EBITDA for Q3 2025, indicating strong operational performance and potential for future growth. (investors.pahc.com)
The company's acquisition of Zoetis's Medicated Feed Additive portfolio has enhanced its market competitiveness and expanded its product offerings. (ainvest.com)
Phibro's stock price has shown a remarkable 101.19% increase over the past year, reflecting strong investor confidence and market performance. (fullratio.com)
The company's net income has declined by 93% year-over-year, raising concerns about profitability and financial health. (fullratio.com)
Phibro's debt-to-equity ratio has increased to 4.21 as of December 31, 2024, indicating higher financial leverage and potential risk. (macrotrends.net)
The company's limited international presence, with approximately 85% of revenue generated from North American markets, may restrict growth opportunities compared to global competitors. (dcfmodeling.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jun 2025.

PAHC Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

PAHC Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $PAHC

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs